SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88111.
  • 2
    Brown RD, Ambler SK, Mitchell MD et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657687.
  • 3
    Sun Y, Kiani MF, Postlethwaite AE et al. Infarct scar as living tissue. Basic Res Cardiol 2002; 97: 343347.
  • 4
    Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res 2000; 46: 250256.
  • 5
    Zlokovic BV. Remodeling after stroke. Nat Med 2006; 12: 390391.
  • 6
    Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 2006: 249282.
  • 7
    Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 4149.
  • 8
    Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 2004; 95: 209214.
  • 9
    Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 920.
  • 10
    Abdel-Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 989997.
  • 11
    Miyahara Y, Nagaya N, Kataoka M et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006; 12: 459465.
  • 12
    Nagaya N, Kangawa K, Itoh T et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112: 11281135.
  • 13
    Ohnishi S, Yanagawa B, Tanaka K et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 2007; 42: 8897.
  • 14
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 18151822.
  • 15
    Jeong JA, Hong SH, Gang EJ et al. Differential gene expression profiling of human umbilical cord blood-derived mesenchymal stem cells by DNA microarray. Stem Cells 2005; 23: 584593.
  • 16
    Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678685.
  • 17
    Ohnishi S, Sumiyoshi H, Kitamura S et al. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007; 581: 39613966.
  • 18
    Sadat S, Gehmert S, Song YH et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007; 363: 674679.
  • 19
    Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008; 17: 199206.
  • 20
    Tang J, Xie Q, Pan G et al. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006; 30: 353361.
  • 21
    Togel F, Weiss K, Yang Y et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626F1635.
  • 22
    Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389397.
  • 23
    Li L, Zhang Y, Li Y et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int 2008; 21: 11811189.
  • 24
    Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 84078411.
  • 25
    Rojas M, Xu J, Woods CR et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145152.
  • 26
    Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70: 121129.
  • 27
    Abdel Aziz MT, Atta HM, Mahfouz S et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem 2007; 40: 893899.
  • 28
    Oyagi S, Hirose M, Kojima M et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol 2006; 44: 742748.
  • 29
    Kasper G, Glaeser JD, Geissler S et al. Matrix metalloprotease activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior. Stem Cells 2007; 25: 19851994.
  • 30
    Zhao ZH, Xin SJ, Zhao JM et al. Dynamic expression of matrix metalloproteinase-2, membrane type-matrix metalloproteinase-2 in experimental hepatic fibrosis and its reversal in rat [in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2004; 18: 328331.
  • 31
    Mias C, Trouche E, Seguelas MH et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 2008; 26: 17491757.
  • 32
    Itoh T, Ikeda T, Gomi H et al. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997; 272: 2238922392.
  • 33
    Xu Q, Norman JT, Shrivastav S et al. In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am J Physiol Renal Physiol 2007; 293: F631F640.
  • 34
    Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 10761084.
  • 35
    Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med 2007; 4( suppl 1): S21S26.
  • 36
    Mishra PK. Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation? J Cardiovasc Med (Hagerstown). 2008; 9: 122128.
  • 37
    Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008; 1: 4.
  • 38
    Azuma J, Taniyama Y, Takeya Y et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006; 13: 12061213.
  • 39
    Inagaki Y, Higashi K, Kushida M et al. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008; 134: 11801190.
  • 40
    Liu Y, Yang J. Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int 2006; 70: 238240.
  • 41
    Sherriff-Tadano R, Ohta A, Morito F et al. Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism. Mod Rheumatol 2006; 16: 364371.
  • 42
    Zhu XY, Zhang XZ, Xu L et al. Transplantation of adipose-derived stem cells overexpressing hHGF into cardiac tissue. Biochem Biophys Res Commun 2009; 379: 10841090.
  • 43
    Schuleri KH, Amado LC, Boyle AJ et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol 2008; 294: H2002H2011.